Alopecia areatahttps://en.wikipedia.org/wiki/Alopecia_areata
Alopecia areata inzvimbo inorasika bvudzi kubva paganda. Kazhinji, inogadzira mhanza diki paganda remusoro, imwe neimwe ichitaridzika sekukura kwemari. Chirwere ichi chinogona kukonzerwa nekusagadzikana mupfungwa.

Alopecia areata inofungidzirwa sechirwere che autoimmune chine chekuita ne immune system yebvudzi follicles. Maitiro ayo anobatanidza kutadza kwemiviri kuziva masero ebvudzi, zvichitevera kuparadzwa kunoitwa ne immune‑mediated kwebvudzi follicle.

Kurapa ― OTC Zvinodhaka
Vamwe vanhu vane alopecia areata vanopora mukati megore vasina kurapwa. Zvisinei, vazhinji vanowanzonzwa kudzokorora munzvimbo dzakabva pakutanga paganda remusoro.
#Hydrocortisone cream

Kurapwa
Majekiseni e steroid anopinzwa mukati (intralesional) ndiwo anonyanya kushandiswa. Immunotherapy inogona kuyedzwa kana nzvimbo huru dzemusoro dzikakanganiswa.
#Triamcinolone intralesional injection
#DPCP immunotherapy
☆ AI Dermatology — Free Service
Mune 2022 Stiftung Warentest mhedzisiro kubva kuGermany, kugutsikana kwevatengi neModelDerm kwakangodzikira zvishoma pane nekubhadharwa kwe telemedicine kubvunzana.
  • Alopecia areata inowanikwa kuseri kwemusoro. Muzviitiko zvakajairika, inowoneka kamwe kamwe iine nzvimbo yakatsetseka uye saizi ye2‑3 cm.
  • Multiple denderedzwa dzebvudzi kurasikirwa.
References Alopecia areata 28300084 
NIH
Alopecia areata ndiyo mamiriro ezvinhu apo immune system yako inorwisa mafollicle ebvudzi rako, zvichitungamira mukurasikirwa kwebvudzi kwenguva pfupi pasina vanga. Inogona kuratidza semapundu ekurasika bvudzi kana kukanganisa ganda rako rose kana muviri, zvichikanganisa 2 % yevanhu panguva imwe muupenyu hwavo. Chinhu chikuru chinoonekwa sekuparara kwekuchengetedzwa kwechisikigo kunotenderedza bvudzi.
Alopecia areata is an autoimmune disorder characterized by transient, non-scarring hair loss and preservation of the hair follicle. Hair loss can take many forms ranging from loss in well-defined patches to diffuse or total hair loss, which can affect all hair-bearing sites. Patchy alopecia areata affecting the scalp is the most common type. Alopecia areata affects nearly 2% of the general population at some point during their lifetime. A breakdown of immune privilege of the hair follicle is thought to be an important driver of alopecia areata.
 Alopecia Areata: An Updated Review for 2023 37340563 
NIH
Alopecia areata imamiriro ekuti immune system inorwisa mafollicles ebvudzi, zvichikonzera kurasikirwa kwebvudzi pamusoro pemusoro uye dzimwe nhengo dzine mvere dzemuviri. Inobata zvakapoteredza 2 % yevanhu pasi rose. Kunyange zvichigona kuitika chero zera, zvinowanzoitika muvana pane vakuru (1.92 % vs. 1.47 %). Vakadzi, kunyanya avo vanopfuura makumi mashanu, vanowanzosangana nazvo kupfuura varume. Kubaya majekiseni e corticosteroids munzvimbo dzakakanganisika kwaratidza zvibereko zviri nani pane kuashandisa pamusoro.
Alopecia areata is an immune-mediated condition leading to non-scarring alopecia of the scalp and other hair-bearing areas of the body. It affects up to 2% of the global population. It can affect all ages, but the prevalence appears higher in children compared to adults (1.92%, 1.47%). A greater incidence has been reported in females than males, especially in patients with late-onset disease, defined as age greater than 50 years. Intralesional injection of corticosteroids has been reported to lead to better responses compared to topical steroids.